PT - JOURNAL ARTICLE AU - Chiara Klöckner AU - J. Pedro Fernandez Murray AU - Mahtab Tavasoli AU - Heinrich Sticht AU - Gisela Stoltenburg-Didinger AU - Leila Motlagh Scholle AU - Somayeh Bakhtiari AU - Michael C. Kruer AU - Hossein Darvish AU - Saghar Ghasemi Firouzabadi AU - Alex Pagnozzi AU - Anju Shukla AU - Katta Mohan Girisha AU - Dhanya Lakshmi Narayanan AU - Parneet Kaur AU - Reza Maroofian AU - Maha S. Zaki AU - Mahmoud M. Noureldeen AU - Andreas Merkenschlager AU - Janina Gburek-Augustat AU - Elisa Cali AU - Selina Banu AU - Kamrun Nahar AU - Stephanie Efthymiou AU - Henry Houlden AU - Rami Abou Jamra AU - Jason Williams AU - Christopher R. McMaster AU - Konrad Platzer TI - Bi-allelic variants in <em>CHKA</em> cause a neurodevelopmental disorder with epilepsy and microcephaly AID - 10.1101/2021.10.21.21265050 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.21.21265050 4099 - http://medrxiv.org/content/early/2021/10/31/2021.10.21.21265050.short 4100 - http://medrxiv.org/content/early/2021/10/31/2021.10.21.21265050.full AB - The Kennedy pathways catalyze the de novo synthesis of phosphatidylcholine and phosphatidylethanolamine, the most abundant components of eukaryotic cell membranes. In recent years, these pathways have moved into clinical focus since four out of ten genes involved have been associated with a range of autosomal recessive rare diseases such as a neurodevelopmental disorder with muscular dystrophy (CHKB), bone abnormalities and cone-rod dystrophy (PCYT1A), and spastic paraplegia (PCYT2, SELENOI).We identified six individuals from five families with bi-allelic variants in CHKA presenting with severe global developmental delay, epilepsy, movement disorders, and microcephaly. Using structural molecular modeling and functional testing of the variants in a in a cell-based S. cerevisiae model, we determined that these variants reduce the enzymatic activity of CHKA and confer a significant impairment of the first enzymatic step of the Kennedy pathway.In summary, we present CHKA as a novel autosomal recessive gene for a neurodevelopmental disorder with epilepsy and microcephaly.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMT, JPF-M, and CRM were funded by the Canadian Institutes of Health Research. Supported in part by NIH NS106298 to MCK. SE and HH were supported by an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1. Individuals 3 and 5 were collected as part of the SYNaPS Study Group collaboration funded by The Wellcome Trust and strategic award (Synaptopathies) funding (WT093205 MA and WT104033AIA). This research was conducted as part of the Queen Square Genomics group at University College London, supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of the University of Leipzig, Germany (402/16-ek). All families provided informed consent for clinical testing and publication.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.ACMGAmerican College of Medical GeneticsADPAdenosine diphosphatecMRIcranial MRICOXcytochrome c oxidaseDD/IDdevelopmental delay/intellectual disabilityESexome sequencingH&amp;Ehematoxylin and eosinNMDnonsense-mediated mRNA decayOFCoccipitofrontal circumferenceORFopen reading framePCphosphatidylcholinePEphosphatidylethanolamineRPEretinal pigment epitheliumSDHsuccinate dehydrogenase